Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer. (September 2017)

• Record Type: Journal Article
• Authors: Wei, Xiao; Schlenkhoff, Carl; Schwarz, Bettina; Essler, Markus; Ahmadzadehfar, Hojjat
• Is Part Of: Clinical nuclear medicine. Volume 42:Number 9(2017)
• Publication Date: 2017-09
• Subjects: 177Lu -- brain metastases -- prostate cancer -- PSMA -- radioligand therapy; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000001763
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Two castration-resistant prostate cancer patients, both with cerebral and visceral and lymphatic metastases, received multiple cycles of 177 Lu-PSMA-617 treatments. The prognosis of both cases is dependent on brain metastases. Between 177 Lu-PSMA-617 treatment cycles, local radiotherapy was also applied to the brain metastases. Prior to the combined therapy, all systemic metastases, including cerebral lesions, showed PSMA expression using 68 Ga-PSMA PET/CT. Under the combined therapy, all the metastases, particularly the cerebral lesions, showed significant regression in size and PSMA expression over time.